Multiple Myeloma cancer. Section View Of The Bone Marrow. BSIP/UIG Via Getty Images

Doctors at the University of Pennsylvania will soon utilize the gene-editing tool CRISPR to try to combat cancer, per the MIT Tech Review.

Why it matters: The trial combines gene-editing and immunotherapy, two promising areas of medical research. There is a lot of anticipation about human trials involving CRISPR but there have been delays.

The details: The study will reportedly involve 18 patients with multiple myeloma, sarcoma, and melanoma cancers. The researchers plan to modify the patient's immune cells to make them better at finding and attacking the cancer. By modifying the cells outside of the body, and then infusing them back into the patient's blood, the researchers hope to avoid some of CRISPR's potential side-effects. It is still unclear when the trial will start.

Go deeper

Grand jury indicts ex-officer who shot Breonna Taylor for wanton endangerment

A memorial to Breonna Taylor in downtown Louisville, Kentucky on Sept. 23. Photo: Jeff Dean/AFP via Getty Images

A grand jury has indicted Brett Hankison, one of the Louisville police officers who entered Breonna Taylor's home in March and shot her at least eight times, on three counts of wanton endangerment.

The state of play: None of the three officers involved in the botched drug raid will face charges related to the actual death of Taylor, such as homicide or manslaughter. Two officers were not charged at all.

FDA chief vows agency will not accept political pressure on coronavirus vaccine

Food and Drug Administration Commissioner Stephen Hahn promised that "science will guide our decision" for a coronavirus vaccine at a Senate hearing on Wednesday.

Why it matters: More Americans are expressing doubt about a first-generation vaccine, despite President Trump's efforts to push an unrealistic timeline that conflicts with medical experts in his administration.

CEO confidence rises for the first time in over 2 years

Data: Business Roundtable; Chart: Naema Ahmed/Axios

A closely-watched CEO economic confidence index rose for the first time after declining for nine straight quarters, according to a survey of 150 chief executives of the biggest U.S. companies by trade group Business Roundtable.

Why it matters: The index, which still remains at a decade low, reflects corporate America's expectations for sales, hiring and spending — which plummeted amid uncertainty when the pandemic hit.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!